Literature DB >> 1989649

Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection.

R J Hodgkiss1, G Jones, A Long, J Parrick, K A Smith, M R Stratford, G D Wilson.   

Abstract

Numerous methods have been proposed for the detection of hypoxic cells using nitroimidazoles labelled with both radioactive and stable isotopes where the isotopic label becomes bound as a result of reductive metabolism of the nitro group. A new probe for hypoxia, 7-(4'-(2-nitroimidazol-l-yl)-butyl)-theophylline, is described where an immunologically recognisable hapten (theophylline) is covalently linked to a 2-nitroimidazole. Bioreduction of the nitroimidazole leads to binding of bioreductive metabolites, and hence the theophylline side-chain, to intracellular molecules. Immunochemical procedures are then used to stain cells containing the bound theophylline using an FITC-conjugated anti-serum. Flow cytometric analysis of stained cells is facilitated by co-staining cellular DNA, which allows discrimination of single cells in the sample and rejection of cell clumps and debris. The alternative use of an immunoperoxidase-conjugated anti-serum has been used to demonstrate the localisation of hypoxic cells in frozen tumour sections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989649      PMCID: PMC1971656          DOI: 10.1038/bjc.1991.24

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Regional blood flow by fractional distribution of indicators.

Authors:  L A SAPIRSTEIN
Journal:  Am J Physiol       Date:  1958-04

2.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.

Authors:  L H GRAY; A D CONGER; M EBERT; S HORNSEY; O C SCOTT
Journal:  Br J Radiol       Date:  1953-12       Impact factor: 3.039

3.  Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T.

Authors:  J A Raleigh; A J Franko; E O Treiber; J A Lunt; P S Allen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

4.  The place of oxygen in radiotherapy.

Authors:  I Churchill-Davidson; C A Foster; G Wiernik; C D Collins; N C Pizey; D B Skeggs; P R Purser
Journal:  Br J Radiol       Date:  1966-05       Impact factor: 3.039

5.  Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia.

Authors:  R C Urtasun; J D Chapman; J A Raleigh; A J Franko; C J Koch
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

6.  Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data.

Authors:  J E Moulder; S Rockwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-05       Impact factor: 7.038

7.  Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells.

Authors:  J S Rasey; K A Krohn; Z Grunbaum; P J Conroy; K Bauer; R M Sutherland
Journal:  Radiat Res       Date:  1985-04       Impact factor: 2.841

8.  Definitive evidence for hypoxic cells influencing cure in cancer therapy.

Authors:  R S Bush; R D Jenkin; W E Allt; F A Beale; H Bean; A J Dembo; J F Pringle
Journal:  Br J Cancer Suppl       Date:  1978-06

9.  Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival.

Authors:  J Overgaard; H S Hansen; K Jørgensen; M Hjelm Hansen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

10.  A marker for hypoxic cells in tumours with potential clinical applicability.

Authors:  J D Chapman; A J Franko; J Sharplin
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

View more
  17 in total

Review 1.  Extracellularly activatable nanocarriers for drug delivery to tumors.

Authors:  Sara A Abouelmagd; Hyesun Hyun; Yoon Yeo
Journal:  Expert Opin Drug Deliv       Date:  2014-06-20       Impact factor: 6.648

2.  Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats.

Authors:  P O Jensen; B T Mortensen; R J Hodgkiss; P O Iversen; I J Christensen; N Helledie; J K Larsen
Journal:  Cell Prolif       Date:  2000-12       Impact factor: 6.831

Review 3.  Optimizing hypoxia detection and treatment strategies.

Authors:  Cameron J Koch; Sydney M Evans
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

4.  Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation.

Authors:  D Vordermark; T Shibata; J M Brown
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

Review 5.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 6.  Vascular attack as a therapeutic strategy for cancer.

Authors:  J Denekamp
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

Review 7.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Regulation of EMAP II by hypoxia.

Authors:  Susanne Matschurat; Ulrike E Knies; Veronika Person; Ludger Fink; Benjamin Stoelcker; Chinedu Ebenebe; Heike A Behrensdorf; Jutta Schaper; Matthias Clauss
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

9.  Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo.

Authors:  L Webster; R J Hodgkiss; G D Wilson
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia.

Authors:  S M Evans; K M Laughlin; C R Pugh; C M Sehgal; H M Saunders
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.